Intervention

Icotinib

ClinicalTrials.gov intervention label

Clinical trials49

Recruiting3

Common conditions25

Lead sponsors shown15

Clinical trials

49 shown

Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung CancerNCT07806604 · 2026-09-01

Befotertinib and Icotinib for NSCLC With Uncommon EGFR MutationsNCT06517953 · 2024-07-17

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerNCT05104788 · 2021-10-25

Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsNCT06955325 · 2025-05-01

NOT_YET_RECRUITING

A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete ResectionNCT05514314 · 2022-09-01

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R MutationNCT05263947 · 2022-01-30

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung AdenocarcinomaNCT05132985 · 2022-01-01

NOT_YET_RECRUITING

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung CancerNCT05007938 · 2021-08-12

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLCNCT04797806 · 2021-03-12

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world StudyNCT04575415 · 2020-10-07

Adjuvant Chemotherapy With or Without Intercalated IcotinibNCT03983811 · 2019-07-01

Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.NCT03992885 · 2019-07-01

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung CancerNCT03766490 · 2019-03-30

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung CancerNCT03749213 · 2018-12-01

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR MutationNCT03754530 · 2018-12-01

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung CancerNCT03349203 · 2018-10-01

A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation TherapyNCT04058704 · 2018-07-20

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung CancerNCT03396185 · 2018-05-09

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung CancerNCT03346811 · 2017-11-18

Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR MutationNCT03153358 · 2017-06-02

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR MutationNCT02961270 · 2016-11-01

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLCNCT02960607 · 2016-11-01

The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR MutationNCT02820116 · 2016-05-01

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR MutationNCT02737774 · 2016-04-13

Cryotherapy Combine Icotinib for Advanced NSCLC TreatmentNCT02744664 · 2016-04-01

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain MetastasesNCT02726568 · 2016-03-01

Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationNCT03151161 · 2015-12-01

Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationNCT02448797 · 2015-06-08

Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung CancerNCT02009605 · 2015-03-01

Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line TherapyNCT02362230 · 2015-01-01

Icotinib for Completed Resected IB NSCLC With EGFR MutationNCT02264210 · 2015-01-01

Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung CancerNCT02407366 · 2014-12-01

Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene MutationNCT02283424 · 2014-10-01

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung AdenocarcinomaNCT02125240 · 2014-09-01

Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung CancerNCT02191059 · 2014-07-01

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung AdenocarcinomaNCT02103257 · 2014-03-01

Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target TherapyNCT01963195 · 2014-02-01

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR MutationNCT02044328 · 2014-01-01

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung CancerNCT02031601 · 2014-01-01

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKINCT02066870 · 2014-01-01

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC PatientsNCT01843647 · 2013-04-01

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib TherapyNCT01720901 · 2013-02-01

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung CancerNCT01724801 · 2012-10-14

Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung CancerNCT01688713 · 2012-08-01

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated PatientsNCT01646450 · 2012-07-01

Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung CancerNCT01514877 · 2012-01-01

Dose Escalation Of Icotinib In Previously Treated Patients With Routine DoseNCT01465243 · 2011-09-01

Chemotherapy of NSCLC With or Without IcotinibNCT02430974 · 2011-01-01

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) PatientsNCT01040780 · 2009-02-01

Common conditions

Leading sponsors

Betta Pharmaceuticals Co., Ltd.19 Sun Yat-sen University4 Tianjin Medical University Cancer Institute and Hospital3 Chinese Academy of Medical Sciences2 Guangdong Association of Clinical Trials2 Nanfang Hospital, Southern Medical University2 Zhejiang Cancer Hospital2 Anhui Medical University1 Beijing Haidian Hospital1 Chinese PLA General Hospital1 Fuda Cancer Hospital, Guangzhou1 Henan Cancer Hospital1 Liaoning Cancer Hospital & Institute1 Peking University Cancer Hospital & Institute1 People's Hospital of Guangxi Zhuang Autonomous Region1

Trial status mix

UNKNOWN34

COMPLETED8

RECRUITING3

NOT_YET_RECRUITING2

SUSPENDED1

TERMINATED1

Phase mix

PHASE229

PHASE38

PHASE47

NA2

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.